TransMedics Group
Pairs warm organ perfusion systems with end-to-end transplant procurement and logistics.
Something off on this page? Send us feedback.
Profile
Sells OCS Heart, Lung, and Liver systems, organ-specific disposable sets, and National OCS Program services for organ retrieval, perfusion, and logistics. Recurring transplant-case revenue is concentrated in the United States, where regulated devices are paired with trained clinical teams and dedicated air and ground transport.
Preserves and assesses donor hearts, lungs, and livers outside the body using OCS Heart, OCS Lung, and OCS Liver, portable warm perfusion systems. Revenue comes from organ-specific single-use perfusion sets and solutions, consoles, and National OCS Program services. NOP supplies outsourced organ retrieval, perfusion management, and air and ground logistics to transplant centers, with owned aircraft supporting the U.S. network.
Commercial activity is concentrated in the United States, while international customers mainly buy systems directly and European NOP logistics are expanding through Italy and an investment in Germany-based PAD Aviation. Execution combines regulated devices, recurring disposables, trained procurement and clinical teams, and time-sensitive transport. The model depends on FDA approvals, hospital adoption and reimbursement, single-source supplies, and aviation licenses and capacity.
Company facts
Categories
Key statistics
Year to date −27.9% · Average volume (30d) 881.5K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | Robert W. Baird | Target | $140 | $122 | |
| Aug 5, 2026 | Canaccord Genuity | Target | $124 | $95 | |
| Aug 5, 2026 | Stifel Nicolaus | Target | $80 | $65 | |
| Aug 3, 2026 | Needham | Reiterate | Buy | $142 | $106 |
| Jul 28, 2026 | UBS | Initiate | Neutral | $80 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.50 | $0.44 | −11.2% | $184.0M | $189.9M | +3.2% | −5.28% |
| May 5, 2026Q1 FY26 | $0.62 | $0.30 | −51.6% | $174.4M | $173.9M | −0.3% | −23.19% |
| Feb 24, 2026Q4 FY25 | $0.41 | $0.57 | +39.0% | $155.4M | $160.8M | +3.5% | −4.30% |
| Oct 29, 2025Q3 FY25 | $0.37 | $0.66 | +78.4% | $155.4M | $143.8M | −7.5% | +1.09% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $143.5M | $157.4M | $143.8M | $160.8M | $173.9M | $189.9M | |
| Gross profit | $88.2M | $96.6M | $84.6M | $93.4M | $101.2M | $113.2M | |
| Operating income | $27.4M | $36.6M | $23.3M | $21.3M | $13.3M | $23.7M | |
| Net income | $25.7M | $34.9M | $24.3M | $105.4M | $7.3M | $14.7M | |
| Diluted EPS | $0.70 | $0.92 | $0.66 | $2.59 | $0.20 | $0.41 | |
| Gross margin | 61.5% | 61.4% | 58.8% | 58.1% | 58.2% | 59.6% | |
| Operating margin | 19.1% | 23.2% | 16.2% | 13.2% | 7.6% | 12.5% |
Fiscal years (4-quarter sums)FY21 $30.3M · FY22 $93.5M · FY23 $241.6M · FY24 $441.5M · FY25 $605.5M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $472.7M · Total debt $867.7M · Total assets $1.46B · Shareholders' equity $518.1M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 34.56M · Float 33.54M · 97.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.60M | 16.19% | 13F | Aug 7, 2026 |
| FMR LLC | 5.13M | 14.85% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 1.93M | 5.60% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.50M | 4.33% | 13F | Aug 13, 2026 |
| State Street Corp | 1.42M | 4.11% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 15, 2026 | Thomas J. Gunderson | director | −9,624 | $75.06 |
| Mar 4, 2026 | David Weill | director | −3,571 | $146.82 |
| Mar 4, 2026 | Stephanie Lovell | director | −1,193 | $149.62 |
| Mar 2, 2026 | Nicholas Corcoran | officer: See remarks | −2,966 | $139.12 |
| Mar 2, 2026 | Anil P. Ranganath | officer: See remarks | −864 | $139.12 |
Peers
- United Therapeutics
Lung EVLP service peer through Lung Bioengineering
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| TransMedics Group | $88.62 | +0.21% | $3.06B | 22.9 | 47.0 | 4.6 | +20.7% |
| United Therapeutics | $515.46 | +0.03% | $21.88B | 18.5 | 19.8 | 6.9 | −1.9% |
| Median | 18.5 | 19.8 | 6.9 | −1.9% |



